-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Data on the correlation between interstitial lung disease (ILD) and the natural course of 2019 new coronary pneumonia ( COVID-19 ) are very limited.
The new crown pneumonia COVID-19
Recently, an authoritative journal in the field of respiratory diseases published a research article in Eur Respir J.
infection
From January 1, 2020 to May 30, 2020, researchers formed a nationwide cohort of COVID-19 patients (n=8070) and a 1:15 ratio matched control based on age, gender, and area of residence.
The proportion of ILD patients in the COVID-19 patient cohort was significantly higher than that in the matched cohort (0.
It can be seen that the risk and serious manifestations of COVID-19 infection in ILD patients are significantly higher than that of non-ILD patients .
ILD patients have significantly higher risk and severe manifestations of COVID-19 than non-ILD patients
Original source:
Original source:Hyun Lee,et al.
ersjournals.
com/content/early/2021/04/19/13993003.
04125-2020" target="_blank" rel="noopener">Interstitial lung disease increases susceptibility to and severity of COVID-19 in this message